Brad Gartland
Senior Business Development Manager
Career highlights
- Senior Business Development Manager, evitria AG (Jul 2025–present): Partners with biopharma and biotech companies to advance therapeutic antibody programs through evitria’s transient CHO expression platform, covering monospecific and bispecific antibodies, Fc-engineered formats, antibody fragments (Fab, scFv, VHH), and recombinant proteins.
- Senior Client Manager, Antibody Discovery & Optimization, Charles River Laboratories (Nov 2023–Jul 2025): Led commercial strategy and business development for antibody discovery and optimization services in the US market; applied go-to-market strategy across drug discovery and IP-related service portfolios.
- Senior Account Manager, Charles River Laboratories (Aug 2021–Nov 2023): Managed key client relationships and drove revenue growth across the UK, with a focus on business relationship management and sales strategy.
- Business Development Manager / Global BD Associate, Retrogenix (Jan 2019–Jul 2021): Developed new business in North America and globally for protein interaction screening services, from lead generation through to deal closure.
- Research Scientist, Antibody Discovery, GSK (Sept 2017–Sept 2018): Placement year at GlaxoSmithKline (Stevenage); independently developed a high-throughput receptor binding assay (RBA) adopted department-wide for Biopharm molecule screening; applied ELISA, Design of Experiments (DOE), and mammalian tissue culture techniques.
- Laboratory Scientist, Source BioScience Stability and Bio Storage – Placement (Jul 2016–Aug 2016): Applied GMP, GLP, and GDP standards in blood banking serology laboratory environments (class B cleanrooms); performed quality control testing and aseptic microbiology testing.
Education
- Durham University — BSc Biomedical Sciences with Placement, 2015–2019, First Class Honours Industrial placement at GSK (Biopharm Molecular Discovery). Member of Durham University Rugby League Team, elected Recruitment Officer.
- Rochdale Sixth Form — A Levels, 2013–2015, 1 A*, 3 A’s
- St Cuthberts High School — GCSEs, 2008–2013, 6 A*’s, 5 A’s
Certifications
- Mental Health First Aid Certification, MHFA England (Aug 2021)
- Lean Six Sigma White Belt, Charles River Laboratories (Feb 2023)
- Royal Voluntary Service – Platinum Champion Award (Jun 2022)
Beyond the lab
Brad Gartland is a committed mental health advocate. He is a Trustee of the Stephen Gartland Foundation, a mental health charity established in memory of his father, and has served as DE&I Emotional Health & Wellness Lead at Charles River Laboratories. He co-founded the Walk & Talk Series, a YouTube interview series on mental health, and contributed as Mental Health Editor for Rochdale Style Magazine.
Articles written by Brad Gartland (9)
Brad writes about outsourced antibody expression, recombinant protein production, bispecific and multispecific antibody formats, and strategic considerations for preclinical biopharma programs. His content bridges commercial and scientific perspectives, drawing on direct experience with both discovery-stage research and customer-facing business development.
-
Monoclonal antibody production: Process, Technologies & Steps
Monoclonal antibodies play a significant role in different fields of life sciences and medicine. But how are they produced in the first place?

-
Antibody-Dependent Cellular Cytotoxicity (ADCC) – Definition, Mechanism & Application
Antibody-dependent cellular cytotoxicity is a key process of the immune system’s arsenal to ward off cancerous cells and infections. We show you important definitions and the ADCC mechanism and key facts on ADCC antibodies in this post.

-
HEK293 cells for recombinant antibody production
HEK cells are intensely used in applications like recombinant antibody production. Why? Find out in this article!

-
7 reasons for us to choose Chinese hamster ovary (CHO) cells for recombinant protein production
In this article, we will discuss 7 reasons why we at evitria use CHO cells in recombinant protein production.

-
Therapeutic antibodies: afucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC)
Therapeutic antibodies are the fastest-growing class of biological drugs. Their ability to interact with specific targets means they can be employed for a range of diseases, including cancer, autoimmune and infectious diseases.

-
Transient transfection – which cell lines are the best option?
There are several factors to consider during transient transfection. A very decisive one is the choice of which cell line to use.

-
Antibody production in CHO cells: Advantages & Disadvantages
CHO cells are an essential tool in antibody production. But why should one choose CHO cells instead of other expression systems? Read more to find out!

-
CHO cells – 7 facts about the cell line derived from the ovary of the Chinese hamster
Cells derived from animals like Chinese hamster ovary cells have been cultured and manipulated for use in pharmaceutical compounds for decades. They form the vital basis of a vast number of applications and are perfect tools for research and development.

-
HEK293 cells vs. CHO cells
HEK cells, also known as HEK293, are human embryonic kidney cells which grow in tissue culture and represent a distinct immortalised cell line. Although HEK cells and CHO cells are both used to create antibodies and for therapeutic protein production, they differ in many…


